Inhibition of TGF1 accelerates regeneration of fibrotic rat liver elicited by a novel two-staged hepatectomy
Bo Zhang,Fanzheng Meng,Yao Liu,Yubin Yuan,Jizhou Wang,Dehai Wu,Yifeng Cui,Shugeng Zhang,Hongrui Guo,Shuhang Liang,Wei Wang,Matthew Klos,Sherry Morgenstern,Yufeng Liu,Linmao Sun,Kun Ma,Xirui Liu,Yan Wang,Jihua Han,Guangchao Yang,Chenyang Zheng,Xianying Li,Shuo Zhou,Changyong Ji,Qingquan Bai,Jiabei Wang,Lianxin Liu
DOI: https://doi.org/10.7150/thno.52102
IF: 11.6
2021-01-01
Theranostics
Abstract:Aims: Emerging evidence is demonstrating that rapid regeneration of remnant liver elicited by associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) may be attenuated in fibrotic livers. However, the molecular mechanisms responsible for this process are largely unknown. It is widely acknowledged that the TGF beta(1) signaling axis plays a major role in liver fibrosis. Therefore, the aims of this study were to elucidate the underlying mechanism of liver regeneration during ALPPS with or without fibrosis, specifically focusing on TGF beta(1) signaling. Approach: ALPPS was performed in rat models with N-diethylnitrosamine-induced liver fibrosis and no fibrosis. Functional liver remnant regeneration and expression of TGF beta(1) were analyzed during the ALPPS procedures. Adeno-associated virus-shTGF beta(1) and the small molecule inhibitor LY2157299 (galunisertib) were used separately or in combination to inhibit TGF beta(1) signaling in fibrotic rats. Results: Liver regeneration following ALPPS was lower in fibrotic rats than non-fibrotic rats. TGF beta(1) was a key mediator of postoperative regeneration in fibrotic liver. Interestingly, AAV-shTGF beta(1) accelerated the regeneration of fibrotic functional liver remnant and improved fibrosis, while LY2157299 only enhanced liver regeneration. Moreover, combination treatment elicited a stronger effect. Conclusions: Inhibition of TGF beta(1) accelerated regeneration of fibrotic liver, ameliorated liver fibrosis, and improved liver function following ALPPS. Therefore, TGF beta(1) is a promising therapeutic target in ALPPS to improve fibrotic liver reserve function and prognosis.